MALARONE

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Manufacturer: GlaxoSmithKline LLC

Indicated for:

Primary anetodermaPlaque-form urticaria pigmentosa

FDA-Approved Indications (2)

Primary anetoderma

prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported

Population: all ages

Plaque-form urticaria pigmentosa

treatment of acute, uncomplicated P. falciparum malaria

Population: all ages

Indications & Usage

1 INDICATIONS AND USAGE MALARONE is an antimalarial indicated for: • prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. ( 1.1 ) • treatment of acute, uncomplicated P. falciparum malaria. ( 1.2 ) 1.1 Prevention of Malaria MALARONE is indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. 1.2 Treatment of Malaria MALARONE is indicated for the treatment of acute, uncomplicated P. falciparum malaria. MALARONE has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.